Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: A Patient with Gout Develops Granulomatous Hepatitis

Raj Vachhani, MD, & Angelo L. Gaffo, MD, MSPH  |  Issue: November 2019, October 2008  |  November 16, 2019

Case Presentation

A 45-year-old man with crystal-proven gout, poorly controlled diabetes and chronic kidney disease was lost to follow-up for six years and presented back to the VA clinic in the midst of a gout flare. He stated he had continued taking 100 mg of allopurinol daily, but his serum urate level was 13.8 mg/dL. He described numerous gout flares over the past few months.

He denied fevers, chills, abdominal pain or a change in bowel habits. He reported chronic fatigue and recent weight gain. His vital signs were all within normal limits.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The physical exam showed the patient was obese (BMI 40) and had mild swelling and warmth in all proximal interphalangeal joints, metacarpophalangeal joints and both wrists. His knees and elbows had noticeable warmth, but were without swelling. Chronic tophaceous buildup was easily palpable at numerous joints, and his range of motion was grossly maintained throughout. He was otherwise without abdominal pain, hepatomegaly, lymphadenopathy or rashes.

After management of the acute gout flare, his allopurinol dose was increased, and he was started on daily colchicine for gout flare prophylaxis. He complied with his medication regimen and showed significant symptomatic improvement. Over the next four months, his allopurinol dose was rapidly escalated to 600 mg daily, reducing his serum urate level to 4.8 mg/dL.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Shortly afterward, he was found to have moderately elevated transaminases and a greatly elevated alkaline phosphatase at 308 U/L (upper limit of normal 126 U/L). An abdominal ultrasound showed cirrhosis and interval development of multiple hypo­echoic lesions throughout the liver, concerning for metastatic disease or hepatocellular carcinoma. Computerized tomography (CT) of the abdomen also demonstrated numerous ill-defined hypodense lesions all throughout the liver (see Figure 1), suspicious for metastatic disease, along with a 1.9×2.9 cm mesorectal mass concerning for colorectal cancer.

Figure 1. A CT of the abdomen demonstrated numerous hypodense lesions present in both lobes of the liver, with the largest lesion measuring 2.0 x 3.1 cm.

Figure 1. A CT of the abdomen demonstrated numerous hypodense lesions present in both lobes of the liver, with the largest lesion measuring 2.0 x 3.1 cm.

This was followed up by a magnetic resonance imaging (MRI) scan of his abdomen, which corroborated the previous hepatic findings. All lesions on the MRI were deemed stable since the earlier CT, and no new lesions were noted. We felt it would be unlikely for the hepatic lesions to be metastatic disease due to stable preexisting lesions and the lack of new lesions in this time frame. An ultrasound-guided biopsy was performed, which revealed necrotizing granulomatous disease (see Figure 2).

Given this granulomatous disease and history of polyarthralgia, sarcoidosis was considered. Plain films were updated, and an MRI of his hands was obtained to determine if his arthropathy and liver disease could be due to sarcoidosis; however, the MRI was remarkable only for lesions consistent with a crystalline arthropathy (see Figure 3). Serum angiotensin I-converting enzyme and vitamin D levels were also not supportive of sarcoidosis.

Infectious etiologies were high on the differential for his granulomatous disease, especially after it was noted our patient had a latent tuberculosis (TB) infection when he was a child in the 1980s. He had received at least one month of treatment for latent TB, but was unsure of any further details of his treatment. Acid-fast bacilli and Gomori methenamine silver stains of the biopsy specimen were negative.

An infectious disease specialist was subsequently consulted. The patient denied fevers or chills, but he reported fatigue and recent weight gain.

He had worked as a long-haul truck driver and had a military history with deployment to the Persian Gulf. Serologies obtained for cryptococcus, histoplasma and coccidioides were unremarkable. QuantiFERON-TB Gold was positive, not unexpected given his latent TB infection as a child. A repeat liver biopsy found granulomatous inflammation with focal necrosis in a background of features compatible with cirrhosis, consistent with previous biopsy. The acid-fast bacilli smear was again negative.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Allopurinolgranulomatous hepatitis

Related Articles

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    The Granulomatosis of Wegener’s

    May 16, 2011

    Delving deeper into the nonvasculitis aspects of the disease

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Meet the HEP C Challenge

    December 1, 2008

    Keep a hepatitis C virus infection from hindering RA treatment

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences